Literature DB >> 9655705

Involvement of tachykinin NK3 receptors in citric acid-induced cough and bronchial responses in guinea pigs.

S Daoui1, C Cognon, E Naline, X Emonds-Alt, C Advenier.   

Abstract

Aerosolized citric acid induces several pulmonary effects including bronchoconstriction, airway inflammation, and cough. Evidence from the use of tachykinin NK1 and NK2 receptor antagonists, as well as chronic treatment with high doses of capsaicin, have suggested that these effects are mediated through the release of tachykinins from sensory nerve endings. In the present study, we have investigated the effects of a tachykinin NK3 receptor antagonist, SR 142801 (osanetant), on cough, bronchoconstriction, and bronchial hyperresponsiveness induced by aerosolized citric acid (0.4 M) in guinea pigs. SR 142801, at 0.3 and 1 mg . kg-1 by intraperitoneal route, significantly inhibited cough in conscious guinea pigs by 57 +/- 3 and 62 +/- 10% (n = 8), respectively. In anaesthetized guinea pigs, it failed to inhibit the bronchoconstriction induced by citric acid when given alone but abolished it when combined with the tachykinin NK2 receptor antagonist, SR 48968 (saredutant). In guinea pigs pretreated with thiorphan (1 mg . kg-1), aerosolized citric acid (0.4 M, 1 h) induced airway hyperresponsiveness 24 h later, displayed by an exaggerated response to the bronchoconstrictor effect of acetylcholine. A microvascular leakage hypersensitivity also occurred and was demonstrated by a potentiation of the plasma protein extravasation from bronchial vessels induced by histamine. When given once intraperitoneally at 1 mg . kg-1 30 min before the citric acid exposure, SR 142801 inhibited both hyperresponsiveness to acetylcholine and the potentiation of histamine-induced increase in microvascular permeability. The results suggest that tachykinin NK3 receptors are involved in citric acid-induced effects on airways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655705     DOI: 10.1164/ajrccm.158.1.9705052

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

Review 1.  Cough challenge in the assessment of cough reflex.

Authors:  A H Morice; J A Kastelik; R Thompson
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Cough. 7: Current and future drugs for the treatment of chronic cough.

Authors:  M G Belvisi; P Geppetti
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

3.  Recommendations for the management of cough in adults.

Authors:  A H Morice; L McGarvey; I Pavord
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 4.  Vagal Afferent Innervation of the Airways in Health and Disease.

Authors:  Stuart B Mazzone; Bradley J Undem
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

5.  Acute and 28-Day Repeated Inhalation Toxicity Study of Glycolic Acid in Male Sprague-Dawley Rats.

Authors:  Seong Kwang Lim; Jean Yoo; Haewon Kim; Woong Kim; Ilseob Shim; Byung-Il Yoon; Pilje Kim; Seung DO Yu; Ig-Chun Eom
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

6.  Opposing effects of bronchopulmonary C-fiber subtypes on cough in guinea pigs.

Authors:  Yang-Ling Chou; Nanako Mori; Brendan J Canning
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-29       Impact factor: 3.619

Review 7.  Afferent nerves regulating the cough reflex: mechanisms and mediators of cough in disease.

Authors:  Brendan J Canning
Journal:  Otolaryngol Clin North Am       Date:  2010-02       Impact factor: 3.346

8.  Mechanisms of acid-induced activation of airway afferent nerve fibres in guinea-pig.

Authors:  Marian Kollarik; Bradley J Undem
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

Review 9.  Central mechanisms II: pharmacology of brainstem pathways.

Authors:  D C Bolser
Journal:  Handb Exp Pharmacol       Date:  2009

Review 10.  Central regulation of the cough reflex: therapeutic implications.

Authors:  Brendan J Canning
Journal:  Pulm Pharmacol Ther       Date:  2009-01-20       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.